The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

challenging Novo and competitor Eli Lilly's market positions. Additionally, the U.S. FDA has approved new treatments spanning ...

Eli Lilly, the manufacturer, said Friday that Zepbound should be used for treatment of moderate to severe obstructive sleep ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept. 23 in Children. In a new analysis of national data, researchers at the ...

sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.” On October 28, Eli Lilly and Company (NYSE ...

Continuous positive airway pressure (CPAP) therapy significantly benefits individuals with obstructive sleep apnea. However, nearly half of adults with CPAP devices struggle to maintain consistent ...